ATE187890T1 - Ligandgerichtete enzyme-prodrug therapie - Google Patents

Ligandgerichtete enzyme-prodrug therapie

Info

Publication number
ATE187890T1
ATE187890T1 AT97901190T AT97901190T ATE187890T1 AT E187890 T1 ATE187890 T1 AT E187890T1 AT 97901190 T AT97901190 T AT 97901190T AT 97901190 T AT97901190 T AT 97901190T AT E187890 T1 ATE187890 T1 AT E187890T1
Authority
AT
Austria
Prior art keywords
prodrug therapy
directed enzyme
enzyme prodrug
ligand directed
ligand
Prior art date
Application number
AT97901190T
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE187890T1 publication Critical patent/ATE187890T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
AT97901190T 1996-01-26 1997-01-24 Ligandgerichtete enzyme-prodrug therapie ATE187890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601640.7A GB9601640D0 (en) 1996-01-26 1996-01-26 Ligand directed enzyme prodrug therapy
PCT/GB1997/000221 WO1997026918A2 (en) 1996-01-26 1997-01-24 Ligand directed enzyme prodrug therapy

Publications (1)

Publication Number Publication Date
ATE187890T1 true ATE187890T1 (de) 2000-01-15

Family

ID=10787646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901190T ATE187890T1 (de) 1996-01-26 1997-01-24 Ligandgerichtete enzyme-prodrug therapie

Country Status (9)

Country Link
EP (1) EP0876160B1 (de)
JP (1) JP2000504218A (de)
AT (1) ATE187890T1 (de)
AU (1) AU709238B2 (de)
DE (1) DE69700983D1 (de)
GB (1) GB9601640D0 (de)
NZ (1) NZ326436A (de)
WO (1) WO1997026918A2 (de)
ZA (1) ZA97657B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
CA2323071C (en) * 1998-03-13 2011-06-21 The Burnham Institute Molecules that home to various selected organs or tissues
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
US10947270B2 (en) * 2015-08-27 2021-03-16 National Yang-Ming University Targeted prodrug cytosine deaminase fusion carrier and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
WO1994021679A1 (en) * 1993-03-25 1994-09-29 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
WO1995002420A2 (en) * 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
CA2185671A1 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP0802801A2 (de) * 1994-12-30 1997-10-29 Chiron Corporation Verfahren und zusammensetzungen zur in vivo behandlung der festen tumoren

Also Published As

Publication number Publication date
WO1997026918A3 (en) 1997-10-23
EP0876160B1 (de) 1999-12-22
DE69700983D1 (de) 2000-01-27
EP0876160A2 (de) 1998-11-11
WO1997026918A2 (en) 1997-07-31
AU709238B2 (en) 1999-08-26
GB9601640D0 (en) 1996-03-27
JP2000504218A (ja) 2000-04-11
NZ326436A (en) 1999-03-29
ZA97657B (en) 1997-08-01
AU1453097A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
DE69535916D1 (de) Oberflächenlokalisierte Expression von Enzymen in gengesteuerter Prodrugtherapie
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
SI1051174T2 (sl) Gastroprotektirane omeprazolne mikrogranule, postopek za pridobivanje le-teh in farmacevtski pripravki
AU1951195A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
AR032293A1 (es) Estuche farmaceutico
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
AU8239298A (en) Nucleotide-comprising composition
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU1747295A (en) 4-amino 6-substituted mycophenolic acid and derivatives with immunosuppressive activity
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
AU1287001A (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
DK1800664T3 (da) Farmaceutiske formuleringer til parenteral indgivelse indeholdende epothilon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties